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The Cell Biology of Tau Secretion
Maria Merezhko, Riikka-Liisa Uronen and Henri J. Huttunen*
Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland
The progressive accumulation and spread of misfolded tau protein in the nervous
system is the hallmark of tauopathies, progressive neurodegenerative diseases with
only symptomatic treatments available. A growing body of evidence suggests that
spreading of tau pathology can occur via cell-to-cell transfer involving secretion and
internalization of pathological forms of tau protein followed by templated misfolding
of normal tau in recipient cells. Several studies have addressed the cell biological
mechanisms of tau secretion. It now appears that instead of a single mechanism, cells
can secrete tau via three coexisting pathways: (1) translocation through the plasma
membrane; (2) membranous organelles-based secretion; and (3) ectosomal shedding.
The relative importance of these pathways in the secretion of normal and pathological
tau is still elusive, though. Moreover, glial cells contribute to tau propagation, and the
involvement of different cell types, as well as different secretion pathways, complicates
the understanding of prion-like propagation of tauopathy. One of the important regulators
of tau secretion in neuronal activity, but its mechanistic connection to tau secretion
remains unclear and may involve all three secretion pathways of tau. This review article
summarizes recent advancements in the field of tau secretion with an emphasis on cell
biological aspects of the secretion process and discusses the role of neuronal activity
and glial cells in the spread of pathological forms of tau.
Keywords: tau, unconventional protein secretion, membranous organelles-based secretion, extracellular vesicles,
autophagy, lysosomes, synaptic transmission, glial cells
INTRODUCTION
Neurodegenerative diseases are incurable and disabling conditions characterized by progressive
degeneration and loss of cells, structures, and functions of the nervous system. Although clinically
neurodegenerative disorders (NDDs) have a broad range of manifestations, generally they cause
progressive cognitive and motor dysfunctions (Gan et al., 2018). The majority of NDDs are
sporadic, but hereditary conditions also exist; the examples of the latter include Huntington’s
disease (HD) and spinocerebellar ataxias. Many diseases that are predominantly sporadic with the
multifactorial origin, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), also have
familial forms, typically indistinguishable from the sporadic diseases in their clinical manifestations
and neuropathology (Lippa et al., 1996; Papapetropoulos et al., 2007). Classification of NDDs is
often done neuropathologically based on specific proteins that form insoluble protein deposits
in neurons and/or glia. Diseases with an accumulation of tau aggregates are termed tauopathies
and include AD, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD),
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), argyrophilic
grain disease (AGD), aging-related tau astrogliopathy (ARTAG) and primary age-related tauopathy
(PART; Arendt et al., 2016). Tau aggregates and other disease-characteristic protein deposits,
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however, are not restricted to the associated clinical
profiles—they often coexist in individual patients or can
occur in non-diseased individuals (Spires-Jones et al., 2017;
Yan et al., 2020).
The common feature of multiple neurodegenerative diseases,
including tauopathies, is the progressive accumulation of
misfolded proteins in the nervous system. These misfolded
proteins or their aggregated forms can be transmitted from
affected cells to healthy cells where they can induce templated
misfolding and pathological aggregation of the same type of
protein. This cell-to-cell transmission of pathologically misfolded
and aggregated protein species is now thought to form the
mechanistic basis of disease progression in NDDs. Interestingly,
while the propagation of misfolded protein pathology appears
to be a common mechanism shared by various NDDs, many
NDDs are characterized by the aggregation of specific proteins in
distinctive neuroanatomical patterns and locations in the central
nervous system (CNS) and/or in the peripheral nervous system
(Jucker and Walker, 2013). This review article will address the
mechanisms of tau secretion, the first step in the transcellular
propagation of tau pathology.
TAU PROTEIN IN HEALTH AND DISEASE
Tau is one of the major microtubule-associated proteins (MAPs)
in neurons whose main role is to stabilize microtubules,
supporting cytoskeletal organization, and axonal transport
(Barbier et al., 2019). Recent studies, however, suggest that
instead of stabilizing microtubules, tau may enable them to
have a long labile domain, microtubule fraction with rapid
dynamics (Qiang et al., 2018). Dynamic interaction between tau
and microtubules regulates multiple cellular functions, including
neurite polarity and stability, motor-driven axonal transport of
vesicles and organelles, and, outgrowth, elongation, and guidance
of axons (Caceres and Kosik, 1990; Esmaeli-Azad et al., 1994;
Kempf et al., 1996; Takei et al., 2000; Dixit et al., 2008; Li et al.,
2014; Biswas and Kalil, 2018; Tapia-Rojas et al., 2019). In addition
to its functions as a MAP, tau also plays a role in DNA protection,
adult neurogenesis, synaptic plasticity, regulation of neuronal
activity, and insulin signaling (Hong et al., 2010; Sultan et al.,
2011; DeVos et al., 2013; Kimura et al., 2014; Marciniak et al.,
2017). Besides neurons, tau is also expressed at low levels in
oligodendrocytes and possibly astrocytes (Müller et al., 1997;
Seiberlich et al., 2015; Kovacs, 2020).
The tau protein is composed of four structurally and
functionally distinct domains: (1) N-terminal projection domain;
(2) the central proline-rich domain; (3) microtubule-binding
repeat domain (MTBD); and (4) C-terminal projection domain
(Guo et al., 2017). The primary function of the MTBD, consisting
of three or four imperfectly repeated motifs, is binding to
microtubules (Guo et al., 2017). MTBD can also bind to actin
and crosslink it with microtubules (Cabrales Fontela et al., 2017).
The N-terminal projection domain regulates the binding of tau
to microtubules and determines spacings between them (Chen
et al., 1992; Derisbourg et al., 2015). The proline-rich region
is involved in cell signaling, binding to actin and tubulin (He
et al., 2009; Arendt et al., 2016). A recent study suggested that the
proline-rich region binds tubulin stronger than MTBD and may
have a primary role in microtubule polymerization (McKibben
and Rhoades, 2019). The C-terminal projection domain also
contributes to binding of tau to tubulin and regulates tau binding
to the plasma membrane (Arendt et al., 2016; Kadavath et al.,
2018). As the structure and physiological functions of tau are
beyond the scope of the current review, the readers are referred to
excellent reviews on these topics (Arendt et al., 2016; Guo et al.,
2017; Tapia-Rojas et al., 2019).
The structure of tau is crucial for its functions, but as
tau belongs to a group of intrinsically disordered proteins
(IDPs), it has no stable sequence-defined secondary structure in
solution (Jeganathan et al., 2008). Instead, tau can rapidly adopt
multiple conformations upon interaction with multiple binding
partners, including other proteins, small molecules, membranes,
and nucleic acids (Jeganathan et al., 2008; Georgieva et al.,
2014; Qi et al., 2015; Rauch et al., 2017). Free tau protein,
however, is not entirely in a random coil form. Instead, it tends
to adopt a compact paperclip-like or S-shaped conformation,
which protects tau from aggregation by masking the regions
involved in it (Jeganathan et al., 2006; Elbaum-Garfinkle and
Rhoades, 2012; Zhu et al., 2015). Being an IDP, tau is easily
accessible to post-translational modifications, and a large and
diverse set of modifications (e.g., phosphorylation, acetylation,
methylation, ubiquitination, sumoylation, glycosylation, and
O-GlcNAcylation) are known to regulate tau function (Martin
et al., 2011; Owen and Shewmaker, 2019). Of all modifications,
phosphorylation has a particular importance, as abnormal
phosphorylation of tau strongly contributes to tau aggregation
(Alonso et al., 2001; Zhu et al., 2015). Although, a physiological
cycle of phosphorylation and dephosphorylation is necessary to
maintain biological functions of tau, in pathological conditions
a level of phosphorylation at specific disease-associated sites
increases, reducing tau’s affinity to microtubules (Biernat et al.,
1993; Bramblett et al., 1993; Sengupta et al., 1998; Cho and
Johnson, 2004; Barbier et al., 2019).
Eventually, pathologically phosphorylated (or
hyperphosphorylated) tau detaches from microtubules,
destabilizing the cytoskeleton and compromising axonal
transport (Barbier et al., 2019; Combs et al., 2019). Most
importantly, the accumulating hyperphosphorylated tau in the
cytosol may misfold resulting in the formation of tau aggregates
and fibrils, which are the most prominent hallmarks of
tauopathies (Arendt et al., 2016). Although the tau aggregation
pathway, as well as its filament structure and composition,
are not universal but specific to each tauopathy, in general,
it involves the following steps: (1) acquiring aggregation-
competent conformation that differs from the paperclip-like
conformation of physiological tau in solution; (2) formation
of dimers and small soluble oligomers (pre-tangles); and
(3) formation of filamentous inclusions (Sanders et al., 2014;
Falcon et al., 2018, 2019; Cieplak, 2019). The large insoluble
inclusions of tau, however, are not the most toxic tau species.
They may protect cells from damage by the very toxic small
soluble oligomers of tau through segregating them from the
cell environment into large insoluble inclusions (Cowan and
Mudher, 2013; d’Orange et al., 2018). Besides the intracellular
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toxicity of a certain tau species, their ability to induce damage
also depends on the ability of certain tau species to affect
neighboring cells and propagate the pathology further.
THE TAU PROPAGATION CONCEPT
The stereotypical appearance and progression of tau pathology
differ considerably between tauopathies—the pathology starts in
distinct anatomical areas and in some cases may involve glial
cells in addition to neurons (Braak and Braak, 1995; Williams
et al., 2007; Irwin et al., 2016). Nevertheless, in all tauopathies,
the spread of tau pathology correlates with the progression of the
disease and can be used for their neuropathological staging. For
instance, in AD tau pathology first appears in the transentorhinal
cortex in the medial temporal lobe (Braak stages I/II, or
preclinical AD), then it progresses to limbic regions (Braak stages
III/IV, or prodromal AD) and finally to the neocortex (Braak
stages V/VI, or clinical AD; Braak and Braak, 1995).
In Pick’s disease, tau pathology affects mainly neurons and
to a lesser extent glial cells. Tau-positive inclusions first appear
in frontotemporal limbic/paralimbic and neocortical regions,
then progress to subcortical structures, followed by the primary
motor cortex and precerebellar nuclei, and finally by the
visual cortex (Irwin et al., 2016). In PSP, tau pathology affects
both neuronal and glial cells, starting from the subthalamic
nucleus, pallidum, and substantia nigra, then progressing to the
pedunculopontine nucleus, dentate nucleus, and frontal lobe,
and finally to the temporal lobe (Williams et al., 2007). Tau
pathology in AGD initially develops at the ambient gyrus, then
progresses to the anterior and posterior medial temporal lobe,
and finally affects the septum, insular cortex, and anterior
cingulate gyrus (Saito et al., 2004). Despite the differences in
the stereotypical neuropathological patterns in these disorders,
the pathology in tauopathies, as well as in other NDDs, seems
to spread along neuroanatomically connected brain areas (Raj
et al., 2012; Pandya et al., 2017). The hypothesis of prion-like
propagation offers an elegant explanation of this phenomenon
(Mudher et al., 2017).
Prions are infectious misfolded proteins that can move from
cell to cell and transmit their misfolded conformation, ‘‘a prion
template,’’ to their native ‘‘healthy’’ versions in the previously
unaffected cells, thus propagating the pathology in a template-
directed manner (Sigurdson et al., 2019). Many proteins involved
in NDDs, including Aβ, α-synuclein (α-syn) and tau, although
they are not prions themselves, possess prion-like properties.
This means that certain misfolded forms of these proteins can
be transmitted from a diseased neuron to an unaffected neuron,
where they can induce further misfolding and aggregation of the
native forms of the protein (Jucker and Walker, 2018).
Indeed, numerous studies have demonstrated that extracts
from diseased human or mouse brain transferred to healthy
cells, intracerebrally injected or even peripherally administrated
to wild-type mice or mouse disease models, can seed and
propagate the source pathology in a prion-like manner (Kane
et al., 2000; Clavaguera et al., 2009, 2014; Lasagna-Reeves
et al., 2012; Luk et al., 2012). Furthermore, grafting of dura
matter infected with prions causing iatrogenic Creutzfeldt-Jakob
disease (iCJD), which frequently associates with Aβ deposition,
provided an opportunity to study graft to host transmission
of Aβ in the human brain (Frontzek et al., 2016; Hamaguchi
et al., 2016). Additionally, post mortem analysis of brains from
Parkinson’s and HD patients who had received embryonic tissue
grafts revealed transmission in the opposite direction, from
host to graft, of α-syn, huntingtin protein and tau (Kordower
et al., 2008; Cicchetti et al., 2014; Cisbani et al., 2017). Finally,
an examination of several cases of iCJD that appears to be
linked to the treatment in childhood with human tissue-derived
growth hormone, which may have contained CJD prions and
Aβ, suggested that Aβ may also traffic from the periphery
to the brain and induce Aβ pathology (Ritchie et al., 2017;
Purro et al., 2018).
THE MECHANISM OF TAU PROPAGATION
The prion-like propagation of tauopathies involves the following
steps: (1) generation of a seed, a tau unit able to propagate the
pathology; (2) secretion of seed-competent tau from a diseased
cell; (3) uptake of seed-competent tau by an unaffected cell;
and (4) templated misfolding generating new tau seeds in the
recipient cell.
For tau, a single misfolded protein in a specific conformation
can seed aggregation (Michel et al., 2014; Mirbaha et al., 2018;
Sharma et al., 2018). Seed-competent tau monomers have been
reported to form morphologically distinct ‘‘strains’’ in different
tauopathies, meaning that a conformation of tau in a given seed
will define the distinct type of inclusions, rate of spread, and
pattern of the neuropathological lesion in each disease (Sanders
et al., 2014; Kaufman et al., 2016; Narasimhan et al., 2017; Sharma
et al., 2018). All these properties can be replicated in the process
of cell-to-cell transmission in vitro and in vivo. Indeed, numerous
studies have demonstrated that intracranial injections of tau
strains derived from distinct tauopathies into healthy wild-type
animals resulted in the development of patterns of tau pathology
similar to the source tauopathy (Clavaguera et al., 2013; Sanders
et al., 2014; Boluda et al., 2015; Kaufman et al., 2016; Narasimhan
et al., 2017). Additionally, exposure of cultured cells to distinct
tau strains resulted in the formation of morphologically similar
tau inclusions as in the source tauopathy, and this process
could be faithfully replicated in vivo over many generations
of mice (Sanders et al., 2014). Interestingly, while tau in AD
forms a single strain, tau in CBD forms three sub-strains
and monomers from any of these strains can induce the
formation of all three sub-strains when inoculated into naïve cells
(Sharma et al., 2018).
Pathogenic seeds need to exit donor cells for tau pathology
to propagate. They can follow one of the several potential
secretion pathways to reach the extracellular. The possible
mechanisms of tau secretion include: (1) translocation through
the plasma membrane; (2) membranous organelle-based
secretion (MOBS); and (3) ectosomal secretion (Lonati
et al., 2018; Kang et al., 2019; Pernègre et al., 2019). These
secretion mechanisms of tau are reviewed in more detail in the
following sections.
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Tau does not spread randomly but appears to follow a disease-
specific spatiotemporal pattern based on anatomically connected
neuronal networks, meaning that a presynaptic neuron secretes
tau and a post-synaptic neuron takes it up. Neuronal activity
may play an important role in the trans-synaptic transfer, as
it has been demonstrated to stimulate both tau secretion by
neurons and tau propagation in tissue (Pooler et al., 2013;
Yamada et al., 2014; Wu et al., 2016). The activity-stimulated
trans-synaptic transfer, however, may not be the only way of
cell-to-cell transmission of tau, as the process is known to occur
also in a retrograde direction along a neuronal network. Thus,
interstitial diffusion or microglia-assisted mechanisms also likely
contribute to the propagation process (Ahmed et al., 2014; Asai
et al., 2015; Takeda et al., 2015).
Secreted tau reaches the surface of a recipient neuron in
either free naked form or inside of extracellular vesicles. Recent
studies have shown that both aggregated and monomeric free tau
can be internalized by rapid dynamin-dependent endocytosis,
independent of clathrin, while monomeric tau can also undergo
slower actin-dependent macropinocytosis (Holmes et al., 2013;
Wu et al., 2013; Evans et al., 2018). M1/M3 muscarinic
receptor and low-density lipoprotein receptor-related protein
1 (LRP1) may serve as receptors that trigger tau endocytosis
(Morozova et al., 2019; Rauch et al., 2020). Cell-surface heparan
sulfate proteoglycans (HSPGs), e.g., syndecans, also facilitate
endocytosis by recruiting tau molecules to the plasma membrane
(Holmes et al., 2013; Rauch et al., 2018; Hudák et al., 2019; Zhao
et al., 2020). In both internalization pathways, tau enters the
cytosol of recipient neurons inside vesicular structures, either
endosomes or macropinosomes, but later it escapes these vesicles,
possibly by permeabilization of the endosome membrane to get
access to native tau in the cytosol to initiate templated misfolding
(Calafate et al., 2016).
Tau secreted inside vesicles, such as exosomes, undergoes
uptake by recipient cells as well (Polanco et al., 2016; Wang
et al., 2017). Although these pathways have not been
specifically demonstrated for tau internalization, cells can
internalize extracellular vesicles by multiple pathways, including
clathrin-dependent and clathrin-independent endocytosis,
macropinocytosis, phagocytosis, cholesterol/sphingomyelin
rich domains-mediated internalization, and membrane fusion
(Mulcahy et al., 2014).
Besides secretion and uptake, tau transfer can occur via
tunneling nanotubes, filamentous actin-containing membranous
structures that transiently connect cytosols of cells and mediate
the selective transfer of organelles, vesicles, proteins, and small
molecules between connected cells (Abounit et al., 2016b;
Tardivel et al., 2016; Ariazi et al., 2017). Furthermore, tau
and other prion-like proteins implicated in neurodegenerative
diseases do not only use tunneling nanotubes for transfer but also
promote their formation and, therefore, their transfer between
cells (Costanzo et al., 2013; Abounit et al., 2016a,b; Tardivel et al.,
2016; Rostami et al., 2017). In theory, tau can be transferred
between cells through the tunneling nanotubes both as a free
protein or inside of vesicular structures such as late endosomes
(LE)/lysosomes. Readers interested in more detailed reviews
in the field of tau propagation are referred to the following
insightful articles (Goedert et al., 2017; Mudher et al., 2017;
Jucker and Walker, 2018; Gibbons et al., 2019; Peng et al., 2020).
TAU SECRETION
Proteins can be secreted to the extracellular space via
multiple mechanisms classified as either conventional/classical
or unconventional pathways. The vast majority of secreted
proteins follow a well-studied conventional secretory route, also
known as the endoplasmic reticulum (ER)-Golgi pathway. This
pathway is devoted to proteins that contain a signal peptide (also
known as a leader sequence), generally at the N-terminus.
Proteins without a signal peptide (also called leaderless
proteins) can follow one of four unconventional secretory
pathways: (1) direct translocation through the plasma membrane
through a self-made pore; (2) ATP-binding cassette (ABC)
transporter-based secretion; (3) membranous organelles-
based unconventional secretion (MOBS); and (4) microvesicle
shedding at the plasma membrane (Nickel and Rabouille, 2009;
Rabouille, 2017; Lee and Ye, 2018). While the first two pathways
always result in the secretion of a protein to the extracellular
space in a free form, non-bound to any vesicles, the third
pathway may result in the secretion of either free protein or a
protein inside the small vesicles called exosomes. The fourth
pathway always results in the secretion of a protein inside
large membrane-derived vesicles, called ectosomes. A common
feature of the unconventional protein secretion pathways is that
in most cases they are induced by various types of cellular stress
(Giuliani et al., 2011; Kim et al., 2018).
Tau being a cytosolic leaderless protein, normally bound
to microtubules is anticipated to follow the unconventional
secretory pathways. Indeed, several studies have demonstrated
that tau does not follow the ER-Golgi pathway for secretion
but multiple unconventional secretory pathways (Figure 1; Chai
et al., 2012; Karch et al., 2012; Plouffe et al., 2012; Dujardin et al.,
2014; Tang et al., 2015; Fontaine et al., 2016; Katsinelos et al.,
2018; Merezhko et al., 2018). Interestingly, it appears that out
of these four unconventional secretory pathways for cytosolic
proteins, only ABC transporter-based secretion, dedicated to
acylated peptides and proteins (Rabouille et al., 2012), has
never been shown to mediate tau secretion. It should be
emphasized that so far tau secretion via unconventional secretion
pathways has been demonstrated only with in vitro models.
Table 1 summarizes findings from the key studies addressing tau
secretion mechanisms.
DIRECT TRANSLOCATION THROUGH THE
PLASMA MEMBRANE
Some cytosolic leaderless proteins translocate directly across
the plasma membrane to reach the extracellular space as
a free protein. The most studied protein that follows this
secretory pathway is fibroblast growth factor 2 (FGF2), a
secreted growth factor that lacks a signal peptide (Steringer
and Nickel, 2018). FGF2 secretion involves the following key
steps: (1) recruitment of FGF2 to the plasma membrane by
interaction with PI(4,5)P2 and the Na/K-ATPase (ATP1A1;
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FIGURE 1 | Pathways involved in tau secretion. (1) Direct translocation
through the plasma membrane involves the interaction of tau with specific
lipids, such as PI(4,5)P2 (not shown), at the inner leaflet of the plasma
membrane and interaction with HSPGs at the outer leaflet of the plasma
membrane that facilitates the release of tau to the extracellular space.
(2) Exosomal secretion involves tau uptake into intraluminal vesicles (ILVs) of
LE/Multivesicular bodies (MVBs) by their inward budding and subsequent
release of these ILV (now termed exosomes) via fusion of LE/MVBs with the
plasma membrane. (3) Autophagy-based secretion involves sequestration of
tau by an expanding phagophore and fusion of the resulting autophagosome
with the plasma membrane to release tau. Autophagosome may also first
fuse with LE/MVB on its pathway to the plasma membrane.
(4) LE/lysosome-mediated secretion (misfolding-associated protein secretion,
MAPS) involves the capture of tau by USP19 at the ER membrane,
subsequent translocation of tau into the lumen of closely contacting
LE/lysosomes, facilitated by Hsc70 and its LE/Lys chaperone DNAJC5, and
fusion of LE/lysosome with the plasma membrane to release vesicle-free tau.
(5) Ectosomal secretion involves the budding of tau-containing extracellular
vesicles directly from the plasma membrane to release tau inside vesicles,
which are typically larger than exosomes and have different membrane
compositions. AP, autophagosome; EE, early endosome; HSPG, heparan
sulfate proteoglycans; LE, late endosome; MVB, multivesicular body.
Temmerman et al., 2008; Zacherl et al., 2015);
(2) phosphorylation of FGF2 by the Tec-kinase (Ebert
et al., 2010); (3) PI(4,5)P2-dependent oligomerization of
FGF2 and membrane pore formation (Steringer et al., 2012);
and (4) binding to heparan-sulfate chains of cell surface HSPGs
resulting in translocation of FGF2 molecules to the extracellular
side (Zehe et al., 2006; Nickel, 2007; Steringer and Nickel, 2018).
Another well-studied protein that follows this secretory pathway
is the human immunodeficiency virus type 1 transactivator of
transcription (HIV-Tat), whose secretion is similar to FGF2 with
some distinctive features (Rayne et al., 2010; Zeitler et al., 2015;
Agostini et al., 2017). Recent studies in immortal cell lines and
rodent neuronal cultures suggest that another protein that can
follow this unconventional secretory pathway is tau (Katsinelos
et al., 2018; Merezhko et al., 2018).
The first hint for direct secretion came from the observation
that the majority of tau in the extracellular media or human
CSF appears as vesicle-free protein (Chai et al., 2012; Karch
et al., 2012; Plouffe et al., 2012; Dujardin et al., 2014; Yan et al.,
2016; Wang et al., 2017; Guix et al., 2018; Katsinelos et al.,
2018). Besides translocation through the plasma membrane,
however, free tau may originate from autophagy-based secretion
and LE/lysosomal secretion, two sub-types of MOBS. Tau
secretion, however, was shown to be independent of Ca2+ and
ATP, strongly suggesting that the process does not involve
membrane fusion events in these cells, which excludes MOBS
(Karch et al., 2012; Merezhko et al., 2018). Further, tau was not
found to localize in vesicles, multivesicular bodies (MVBs), or
any other intracellular vesicular compartments in cultured cells
and was found only in minute quantities in exosomal media
fraction produced by tau-expressing cells (Katsinelos et al., 2018;
Merezhko et al., 2018). Tau localization at the plasma membrane,
on the other hand, has been commonly observed.
The further similarities between the secretion of FGF2 and tau
all point out to the ability of tau to follow an FGF2-like secretion
pathway. First, tau secretion, as well as FGF2 secretion, involves
PI(4,5)P2 (Katsinelos et al., 2018). Katsinelos et al. (2018)
demonstrated that tau could bind to immobilized PI(4,5)P2
and this binding seemed to be required for binding of tau
to the membrane. Furthermore, treatment with an antibiotic
that blocks the interaction of proteins with phosphoinositides
suppressed secretion of phosphomimetic mutant of tau in
cultured cells (Katsinelos et al., 2018). Tau binding to the plasma
membrane, however, may not solely rely on PI(4,5)P2, as is the
case with FGF2, but resembles HIV-Tat protein, which can bind
to a range of acidic membrane lipids at the inner leaflet of the
plasma membrane (Temmerman et al., 2008; Zeitler et al., 2015;
Katsinelos et al., 2018).
Binding of FGF2 to PI(4,5P)2 seems to be facilitated by
cholesterol and sphingomyelin, although both lipids are not
essential for the process (Temmerman et al., 2008; Steringer et al.,
2017). Accordingly, both cholesterol and sphingomyelin also
support the secretion of tau (Merezhko et al., 2018). Cholesterol
and sphingomyelin may exert their effect via the formation
of cholesterol/sphingomyelin-rich microdomains that cluster
together molecular components required for FGF2 and tau
secretion such as PI(4,5)P2 (Pike and Miller, 1998; Johnson et al.,
2008). Indeed, several studies have reported that tau localizes
to cholesterol/sphingomyelin-rich membrane microdomains in
the brain of AD patients, mouse models of AD, and in
cell culture (Kawarabayashi et al., 2004; Hernandez et al.,
2009; Collin et al., 2014). Furthermore, tau was shown to
localize to the plasma membrane in small clusters, which
could represent cholesterol/sphingomyelin-rich microdomains
(Merezhko et al., 2018).
Second, the secretion of both FGF2 and tau involves
phosphorylation (Plouffe et al., 2012; Katsinelos et al., 2018;
Merezhko et al., 2018). Although FGF2 secretion requires
specific phosphorylation by the Tec-kinase at tyrosine 82,
phosphorylation at multiple sites seems to drive tau secretion
(Ebert et al., 2010; Plouffe et al., 2012; Katsinelos et al., 2018;
Merezhko et al., 2018). Accordingly, as compared to wild-type
tau, the expression of a phosphomimetic mutant of tau resulted
in a higher level of tau detected at the extracellular side of the
plasma membrane and in the extracellular media (Plouffe et al.,
2012; Katsinelos et al., 2018).
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Third, tau may undergo secretion via the formation
of a transient membrane pore similar to FGF2 (Steringer
et al., 2012). Tau has been shown to disrupt membranes by
forming pore-like amyloid structures, and post-translational
modifications and pathological mutations enhanced this process
(Lasagna-Reeves et al., 2014; Patel et al., 2015). Katsinelos
et al. (2018) also reported that tau binding to PI(4,5)P2-
containing LUVs was accompanied by local disruption of the
membrane integrity. Additionally, tau secretion may involve
the formation of intermolecular disulfide bridges as occurs
with FGF2 secretion (Müller et al., 2015). Indeed, two
cysteine residues located in the R2 and R3 microtubule-
binding repeats of tau are known to form intermolecular
disulfide bridges in tau dimerization and disulfide cross-linked
tau dimer were shown to have higher seeding efficiency
(Bhattacharya et al., 2001; Kim et al., 2015). The requirement of
disulfide bridge formation in tau secretion, however, remains to
be demonstrated.
Lastly, similarly to FGF2, tau secretion involves HSPGs
on the cell surface, as a decrease in cell surface HSPG level
effectively suppressed tau secretion, which was also observed
in a cell line deficient in proteoglycan biosynthesis (Katsinelos
et al., 2018; Merezhko et al., 2018). Interestingly, even the
presence of HSPG on neighboring cells was sufficient to
facilitate tau secretion (Katsinelos et al., 2018). As tau can
bind to HSPG polysaccharides in vitro (Goedert et al., 1996;
Hasegawa et al., 1997), it seems plausible that HSPG on
the extracellular side of the plasma membrane could bind
to the membrane-embedded tau and facilitate its extraction
to the extracellular space, similar to FGF2 secretion process
(Steringer and Nickel, 2018).
Importantly, tau secreted via membrane translocation can
enter recipient cells and induce tau aggregation, implying the
potential role of this secretory mechanism in tau propagation
(Katsinelos et al., 2018; Merezhko et al., 2018).
MEMBRANOUS ORGANELLE-BASED
SECRETION (MOBS)
Although MOBS comprises several mechanisms, all of them
follow the same basic principle. First, the secreted cytosolic
protein enters a carrier organelle, which subsequently fuses with
the plasma membrane, releasing its content into extracellular
space (Figure 1, pathways 2–4).
Cytosolic proteins can be taken up into intraluminal vesicles
(ILVs) by inward budding of late endosomes (LE)/MVBs,
which may then fuse with the plasma membrane to release
the ILVs to the extracellular space (the secreted ILVs are
called exosomes; Nickel and Rabouille, 2009; Rabouille,
2017). Another option for a cytosolic protein is to enter
the lumen of a LE/lysosome (Rabouille, 2017; Lee and
Ye, 2018). Alternatively, an expanding phagophore may
sequester cytosolic proteins, leading to the formation of an
autophagosome, which fuses with the plasma membrane
instead of a lysosome, also releasing its content to the
extracellular space (Claude-Taupin et al., 2017; Rabouille, 2017).
Cytosolic proteins may also enter the lumen of phagophores
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instead of their cytosolic interior and therefore occupy space
between the autophagosome outer and inner membranes
(Zhang et al., 2015).
Therefore, at least three MOBS sub-pathways exist: exosome-
based, autophagy-based, and LE/lysosome-based secretion
pathways (Rabouille, 2017; Lee and Ye, 2018). Although
it seems that such separation mainly originates from an
organelle that fuses with the plasma membrane, the actual
difference is the organelle entry mechanism for cytosolic
proteins. Thus, exosomal or MVB-based secretion implies the
entry of the cytosolic protein into ILVs during the process
of inward budding, while LE/lysosomal secretion implies
the entry to the lumen of LE/lysosome directly through its
membrane, and autophagosome-based secretion—through
the formation of a phagophore. The entry mechanism also
determines if the contents are secreted in a free form or
inside vesicles.
These sub-pathways, however, do not function independently
but rather co-operate dynamically, potentially releasing a
mixed population of cargo that has entered the organelles
by alternative pathways, which creates challenges in their
mechanistic investigation (Lee and Ye, 2018; Xu J. et al., 2018).
For example, autophagosomes can fuse with LE/MVBs, or
LE/MVBs may contain not only ILVs formed by inward budding
but also free luminal proteins that translocated through its
membrane (Claude-Taupin et al., 2017; Lee and Ye, 2018; Xu J.
et al., 2018). In these two cases, the fusion of the organelles with
the plasma membrane may release the secretory proteins both
inside the vesicles and in a free form.
The endosomal-lysosomal pathway is of great interest in the
context of tau secretion, as it is closely related to MOBS. The
endosomal-lysosomal pathway comprises several very dynamic
compartments, undergoing continuous transformation and
exchange of materials. These compartments are early endosome
(EE), MVB, LE, and lysosome.
EE, the first organelle in the endosomal-lysosomal pathway,
receives the cargo material via fusion with multiple endocytic
vesicles from several internalization routes and sorts the cargo
between tubular extensions and cisternal regions to forward them
for recycling to the plasma membrane and degradation pathways,
respectively (Jovic et al., 2010; Naslavsky and Caplan, 2018). The
membrane in the cisternal region of EE buds inward generating
ILVs comprising membrane cargo that have to be degraded
(Scott et al., 2014). This part of EE detaches, or matures, from
the EE and becomes an MVB (Scott et al., 2014).
MVBs, LEs, and lysosomes are part of a continuum of the
endolysosomal system and can be difficult to distinguish when
defining a secretion mechanism. They share many markers
complicating their identification by immunochemical methods.
Different cell types may also present these organelles very
differently. Nevertheless, the transition from EE to MVBs, LEs,
and lysosomes involve the decrease in luminal pH due to activity
of vacuolar H+-ATPase (V-ATPase), generation of additional
ILVs, change of membrane proteins and lipids, and acquisition
of acid hydrolases (Huotari and Helenius, 2011). For this review,
we will use terms MVBs and LEs interchangeably and the
term LE/lysosome to describe the degradative compartment
including LE, lysosomes, and organelles with characteristics
of both.
Exosome-Based Secretion
Inward budding of the endosomal membrane captures cytosolic
proteins and traps them inside of ILVs. Forming ILV can
sequester a random portion of the cytosol, thus acquiring
material unselectively, or work with high precision to acquire
specific molecules (Sahu et al., 2011; Villarroya-Beltri et al.,
2014). For example, cytosolic proteins containing KFERQ
sequence motif are selectively delivered into the forming ILVs by
the cooperation of the cytosolic chaperone Hsc70 and endosomal
sorting complexes required for transport (ESCRTs), which play
an important role in the formation of these vesicles (Sahu
et al., 2011; Hurley, 2015). Naturally, not only cytosolic proteins
are selectively acquired by forming ILVs, but also membrane
proteins, lipids, and RNAs.
The resulting MVBs would either fuse with a lysosome to
degrade their contents, or fuse with the plasma membrane and
release the ILVs into the extracellular space. The mechanism
that regulates the ‘‘fusion fate’’ of MVBs is not clear. One
possibility is the existence of special populations of MVBs that
can fuse with the plasma membrane; these populations may
arise from different sorting mechanisms, resulting in distinct
cargo inside of ILVs and the distinct fate of MVBs. For instance,
sorting of proteins for degradation may occur via ESCRT-
dependent ILVs, giving rise to a population of MVBs that fuses
with lysosomes; while sorting of proteins for secretion may
occur via lipid microdomain-dependent ILVs, giving rise to
a population of MVBs that fuses with the plasma membrane
(Trajkovic et al., 2008). Furthermore, the lipid microdomains
on the membrane of MVBs may also control their fusion with
the plasma membrane, thus providing secretion of specific cargo
(Möbius et al., 2002). Nevertheless, MVBs aimed for secretion
translocate along microtubules, dock at the plasma membrane,
and undergo Ca2+-regulated fusion, which is dependent on
soluble N-ethylmaleimide-sensitive factor attachment protein
receptors (SNAREs), providing multiple additional levels of
regulation of exosomal secretion (Hessvik and Llorente, 2018).
Exosome-dependent secretion is the first proposed and
perhaps the most studied mechanism for tau secretion (Saman
et al., 2012). Endogenous and overexpressed tau have been
detected in exosomes from immortal cell lines, rodent neuronal
cultures, human iPSC neurons, mouse brain, and from CSF of
AD patients (Saman et al., 2012; Dujardin et al., 2014; Tang
et al., 2015; Polanco et al., 2016; Wang et al., 2017; Guix et al.,
2018). Conversely, a large number of studies failed to detect
either endogenous or overexpressed tau in exosomes from the
culture media of cell lines or rodent primary neurons (Fauré
et al., 2006; Chai et al., 2012; Karch et al., 2012; Plouffe et al.,
2012; Santa-Maria et al., 2012). Other studies, however, reported
a presence of a small pool of extracellular tau inside the vesicles
(generally less than 10% of total extracellular tau) from both cell
and animal models, and human CSF (Chai et al., 2012; Wegmann
et al., 2016; Yan et al., 2016; Wang et al., 2017; Guix et al., 2018;
Katsinelos et al., 2018).
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Although the physiological secretion of tau may occur via the
exosomal pathway, multiple studies emphasize the importance
of exosomal secretion in the propagation of tau pathology. First,
several recent studies have indicated that the exosomal secretion
mechanism contributes to tau secretion more extensively in
pathological conditions (Dujardin et al., 2014; Fiandaca et al.,
2015; Winston et al., 2016; Wang et al., 2017). Furthermore,
exosomes from the CSF of AD patients or controls contained
a higher percentage of oligomerized tau than a non-exosomal
portion (Wang et al., 2017). Additionally, neuronally derived
extracellular vesicles (NDEVs) from patients with mild cognitive
impairment (MCI), AD and AD model systems were able to
deliver pathological tau to unaffected cells, seed tau aggregation
in cell culture and in wild type mice, and induce long-distance
propagation of tau pathology (Baker et al., 2016; Polanco et al.,
2016; Winston et al., 2016, 2019; Wang et al., 2017). In addition
to that, uptake and seeding of aggregation occurred with higher
efficiency with exosomal tau as compared with free tau (Asai
et al., 2015; Yan et al., 2016; Wang et al., 2017). Finally, inhibition
of exosome formation blocked tau propagation in a mouse
model (Asai et al., 2015). Thus, although the exosomal pathway
contributes to the secretion of only a minor portion of tau, it still
may play an important role in the propagation of the pathology.
Autophagy-Based Secretion
Macroautophagy (from here referred to as autophagy) is a
lysosomal degradative pathway in which double-membrane
structures, called autophagosomes, isolate cytosolic constituents
and typically deliver them to lysosomes for degradation by
lysosomal enzymes in a resulting organelle called autolysosome
(Dikic and Elazar, 2018). Alternatively, autophagosomes may
first fuse with MVBs to form the amphisomes, which
subsequently fuse with lysosomes to finally degrade the cargo
(Berg et al., 1998). Nonselective degradation of cytosolic material
by autophagy provides nutrients to maintain cellular homeostasis
and protect the cell from damage under various conditions of
cellular stress, such as amino acid or energy shortage (Dikic
and Elazar, 2018). Autophagy also protects cells from harmful
cytosolic material, such as protein aggregates or damaged
organelles, by highly selective elimination of these structures
(Dikic and Elazar, 2018).
Degradation of the captured material, however, is not
the only possible outcome of autophagy. Instead of fusion
with lysosomes, autophagosomes may release their content to
the extracellular space by fusion with the plasma membrane
(Claude-Taupin et al., 2017). Among the known cargo of
secretory autophagy in mammals are phospholipid-binding
protein Annexin A2 (ANXA2), aggregation-prone α-syn, and the
most studied protein in the context of secretory autophagy in
mammals—the proinflammatory cytokine IL-1β (Dupont et al.,
2011; Ejlerskov et al., 2013; Öhman et al., 2014; Chen et al., 2017;
Minakaki et al., 2018).
An intriguing question in the field of secretory autophagy is
when and how the two autophagy pathways diverge. The precise
mechanism that separates these pathways is still rather elusive,
but several recent articles are starting to shape our understanding
of the machinery that mediates secretory autophagy. It appears
that the differences may originate at the stage of the cargo
selection in the expanding phagophore. In selective autophagy,
unique or tag-specific autophagy receptors simultaneously bind
the cargo material and autophagy-related protein 8 (ATG8)-
family proteins on the phagophore membrane, thus tethering the
cargo to the phagophore (Zaffagnini and Martens, 2016). Kimura
et al. (2017) have recently identified the first autophagy receptor
specific for the secretory autophagy of IL-1β in response to
lysosomal damage—TRIM16 (Kimura et al., 2017). This receptor
tethers activated IL-1β and result in different utilization of the
SNAREs by an autophagosome to mediate the fusion with the
plasma membrane instead of a lysosome.
Although multiple aspects of the secretory autophagy remain
unclear, several recent articles imply that tau may also follow this
secretory pathway. Indeed, the accumulation of autophagosomes
and the presence of tau in these structures is a prominent feature
in AD and other tauopathies, so it would not be surprising if
some of these structures would be redirected for secretion (Piras
et al., 2016). Furthermore, a recent study presented electron
microscopy images of presumably tau-containing autophagic
vacuoles approaching the plasma membrane and possibly
releasing free tau in neuroblastoma cells (Tang et al., 2015).
Accumulation of autophagosomes that can be redirected for
secretion in tauopathies may arise from enhanced induction
of autophagy, impaired lysosomal clearance, or a combination
of both. In several studies in neuroblastoma cells and rodent
primary neuron cultures, induction of autophagy by either
starvation or pharmacological agents was shown to enhance tau
secretion, while inhibition of autophagy suppressed it (Mohamed
et al., 2014; Lonati et al., 2018; Kang et al., 2019). In other
studies, however, the inverse relationship between the induction
of autophagy and tau suppression was observed (Tang et al.,
2015; Chen et al., 2020). The conflicting results might arise from
the dual role of autophagy in tau pathophysiology. Although
in any case induction of autophagy results in autophagosome
accumulation, the organelles may be directed for degradation
or secretion, yielding opposing results on tau secretion. For
instance, in one of the studies, where induction of autophagy by
oxygen-glucose deprivation in rodent neuronal culture resulted
in elevated tau secretion, activation of caspase-3 was reported,
which redirects autophagy from degradation to secretion (Sirois
et al., 2012; Lonati et al., 2018).
The accumulation of autophagosomes apparent in
tauopathies may result not only from increased induction
of autophagy but also from impaired lysosomal degradation.
Indeed, impairing autophagosome-lysosome fusion or inhibition
of lysosomal function both enhanced tau secretion, as was
the case for the α-syn (Ejlerskov et al., 2013; Mohamed et al.,
2014; Kang et al., 2019; Chen et al., 2020). Such manipulations,
however, are not that straightforward to interpret, as they may
also affect lysosomal secretion.
Interestingly, amphisomes can also secrete their content upon
fusion with the plasma membrane and it appears that both tau
and α-syn may undergo secretion in these organelles (Claude-
Taupin et al., 2017; Lonati et al., 2018; Minakaki et al., 2018).
Lonati et al. (2018) demonstrated that induction of autophagy
by starvation, though enhanced secretion of free tau, elevated
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the secretion of vesicular tau to a greater extend. They also
demonstrated the increase of autophagosome marker LC3 in
these extracellular vesicles, which implies the possibility of tau
secretion via amphisomes. Although it is also possible that the
majority of tau may arrive in amphisomes via MVBs instead
of autophagosomes since starvation is known to direct MVBs
from exosomal release to fusion with autophagic vacuole to form
amphisomes (Fader et al., 2008).
Currently, it is still unclear if tau uses autophagosomes
as a carrier in the secretion process. Factors that complicate
interpretation of this data include: (1) localization of tau in
autophagosomes and amphisomes could simply reflect tau
degradation by autophagy; (2) altering the level of autophagy-
related proteins may have an impact on other processes in cells;
and (3) close connection between autophagy and other pathways
of unconventional secretion (Xu J. et al., 2018).
Late Endosomal/Lysosomal Secretion
In some cells (including immune cells, astrocytes, and
catecholaminergic neurons) specialized secretory lysosomes
(called lysosome-related organelles) execute regulated secretion
(Luzio et al., 2014). Conventional LEs/lysosomes in other cell
types, however, are also able to secrete their content (Luzio et al.,
2014; Lee and Ye, 2018). Besides having a role in unconventional
protein secretion, this process is also essential for plasma
membrane repair (Samie and Xu, 2014).
Chaperone-mediated autophagy (CMA) delivers cytosolic
proteins into the LE/lysosomes (Lee and Ye, 2018). Regularly,
CMA involves the recognition of cytosolic proteins containing
a KFERQ-like motif by heat shock cognate 71 kDa protein
(Hsc70) and its co-chaperones, followed by unfolding-coupled
translocation to the lumen of LE/lysosome mediated by LAMP2A
protein on the membrane of this organelle (Kaushik et al., 2011).
LE/lysosomal secretion of misfolded proteins involves a similar
organelle entry mechanism, which is called the misfolding-
associated protein secretion pathway (MAPS). During cellular
stress and overloading of the ubiquitin-proteasome system,
MAPS functions to translocate misfolded cytosolic proteins,
including tau and other neurodegeneration disease-associated
proteins, to LEs/lysosomes for secretion to extracellular space
(Fontaine et al., 2016; Lee et al., 2016). In this pathway,
ubiquitin carboxyl-terminal hydrolase 19 (USP19) uses its
chaperone activity to capture a misfolded cytosolic protein
at the extracellular surface of the ER (Lee et al., 2016).
Following capture, Hsc70 and it’s co-chaperone DnaJ heat shock
protein family member C5 (DNAJC5) translocate the cargo
protein into the lumen of LE/lysosome that associates with
ER; in this process, DNAJC5 translocates into the lumen of
LE/lysosome and undergoes secretion together with a cargo
protein (Xu Y. et al., 2018).
Although this mechanism reminds CMA as it also utilizes
Hsc70 and involves a protein translocation through the
LE/lysosomal membrane, MAPS is very different (Lee and
Ye, 2018). CMA pathway captures proteins containing the
KFERQ-like motif and requires unfolding during translocation,
while the MAPS pathway is specific for misfolded proteins and
can translocate them to LE/lysosome without unfolding (Chiang
and Dice, 1988; Lee et al., 2018). These pathways also have
opposing regulatory mechanisms; for example, cellular starvation
activates CMA but inhibits the MAPS pathway (Cuervo et al.,
1995; Lee et al., 2018).
Besides cargo loading, LE/lysosomal secretion involves three
additional steps, the same as in exosomal secretion. First,
upon stimulation LEs/lysosomes are transported along the
microtubules from perinuclear and cytosolic areas to the cell
periphery; this translocation changes the properties of these
organelles (Spampanato et al., 2013; Johnson et al., 2016; Pu et al.,
2016). Peripheral LEs/lysosomes are less acidic, have impaired
proteolytic activity, and have a slightly different composition,
compared to perinuclear ones (Johnson et al., 2016). Following
tethering, LEs/lysosomes are tightly docked to the plasma
membrane by the preassembly of the SNARE complex, consisting
of LE/lysosomal VAMP7 or VAMP8 and the plasma membrane
SNAP23 and possibly syntaxin-4 (Rao et al., 2004; Samie and
Xu, 2014; Fontaine et al., 2016; Lee et al., 2016). In the last
stage, LE/lysosomes fuse with the plasma membrane; the fusion is
triggered by a localized rise in intracellular Ca2+ level (Rodríguez
et al., 1997; Reddy et al., 2001; Savina et al., 2003; Liu et al., 2011;
Medina et al., 2011).
Originally, two publications suggested that tau can undergo
secretion via the MAPS pathway at least in various in vitro
models (see Table 1, Fontaine et al., 2016; Xu Y. et al., 2018). In
2016, Fontaine and colleagues (Fontaine et al., 2016) described
a mechanism of tau secretion that depends on DNAJC5-
Hsc70 complex and involves encapsulation of cargo to an
unidentified membranous compartment that fuses with the
plasma membrane. At the same time, Lee et al. (2016) described
a USP19-dependent mechanism for the selective secretion of
misfolded proteins and named this pathway the MAPS (Lee
et al., 2016). Only the extensive results obtained by Xu Y.
et al. (2018) 2 years later, however, allowed to realize that the
mechanism described by Fontaine is MAPS and that tau is
one of the MAPS cargos. Additional support for these findings
came from Rodríguez et al. (1997), showing that Rab7 GTPase
positively regulates the secretion of free tau, suggesting the
contribution of LE/lysosomes in the secretion as Rab7 is essential
for their maturation and trafficking (Rodriguez et al., 2017).
Nevertheless, the role of LE/lysosomes in tau secretion remains
poorly understood and further studies are required to shed more
light on the mechanisms of the MAPS pathway.
Interestingly, a recent study by Wiersma et al. (2019) may
explain why some LEs/lysosomes are rerouted for exocytosis
in tauopathies. In this study, seeding of tau pathology
induced the formation of LE/lysosomal structures with a
dense core consisting of degraded endocytic material, called
granulovacuolar degeneration bodies (Wiersma et al., 2019). As
these structures seem to appear in neurons at early stages of tau
pathology development, before the formation of tau aggregates, it
may suggest that LE/lysosomes are facing a shortage of lysosomal
enzymes when attempting to degrade early pathogenic tau
species (Köhler, 2016). To eliminate tau in such circumstances,
LEs/lysosomes may activate the MAPS pathway to compensate
for the shortage of lysosomal enzymes. Prior secretion, however,
LE/lysosome may truncate tau before its MTBD, making the
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secreted species seeding-incompetent and, therefore, alleviating
intracellular tau pathology and tau spreading in the same time
(Xu et al., 2020).
ECTOSOME SHEDDING AT THE PLASMA
MEMBRANE
Exosomes are not the only type of extracellular vesicles that
are used for the secretion of cytosolic leaderless proteins like
tau. The other type is called ectosomes (or microvesicles,
shedding vesicles). Compared to exosomes, they are bigger (with
a diameter of 100–1,000 nm vs. 30–150 nm of exosomes),
have a more irregular shape, and have different membrane
composition (Barteneva et al., 2013; Kalra et al., 2016).
Ectosomes also have a different origin—they bud outward
directly from the plasma membrane. Although the membrane
of ectosomes is formed from the plasma membrane, its
composition can differ considerably owing to the sorting
mechanism involved in ectosome formation (Pollet et al., 2018).
Ectosomes, as well as exosomes, are very heterogeneous: not
only different cell types shed ectosomes via distinct although
poorly understood mechanisms, but different mechanisms of
the ectosome formation may function either simultaneously or
sequentially inside a single cell under different conditions or
stimuli (Meldolesi, 2018).
Formation of ectosomes begins with two primary events:
an increase in Ca2+ concentration and local rearrangement
of plasma membrane lipids and proteins to form membrane
microdomains (van Niel et al., 2018). These events result
in a local loss of interaction between the plasma membrane
and cortical actin cytoskeleton and partial disintegration of
the cytoskeleton mostly by Ca2+-dependent protein degrading
enzymes such as calpains (Yano et al., 1993; Pasquet et al.,
1996; Kalra et al., 2016; Taylor et al., 2017). Additionally, Ca2+-
dependent lipid translocases generate local alterations in the
distribution of phospholipids of the plasma membrane (van
Niel et al., 2018). In particular, phosphatidylserine (PS) and
phosphatidylethanolamine (PE), which are normally actively
sequestered to the inner leaflet of the plasma membrane,
translocate to the outer leaflet (van Meer et al., 2008; van
Niel et al., 2018). Exposure of PS to the outer leaflet of
the plasma membrane causes membrane bending and further
disintegration of the cytoskeleton, enhancing ectosome budding
(Kalra et al., 2016). The resulting ectosomes have PS on the
surface, which allow their identification via probes conjugated
to PS-binding proteins, such as Annexin V (Wang et al., 2015).
The clustering of cholesterol, sphingomyelin, and ceramide,
the product of sphingomyelin hydrolysis, at the plasma
membrane facilitates the externalization of PS and membrane
budding (Kunzelmann-Marche et al., 2002; Bianco et al., 2009;
Pollet et al., 2018).
Stabilization of phospholipid asymmetry, however, failed
to prevent Ca2+-induced ectosome formation, suggesting
the existence of alternative mechanisms (Bucki et al.,
1998). The latter is also supported by the finding of
ectosomes that do not have PS on their outer leaflet
(Elliott et al., 2006; Connor et al., 2010). In the final
step, the activation of small GTPase ADP-ribosylation
factor 6 (ARF6) initiates a cascade of events, leading to
phosphorylation of myosin light chain at the neck of budding
vesicles and subsequent actomyosin contraction, resulting in
pinching off the ectosome (Muralidharan-Chari et al., 2009;
Kalra et al., 2016).
Sorting of cytosolic proteins to ectosomes occurs during their
formation when the cytoskeleton disintegrates facilitating vesicle
formation and access of cytosolic proteins to the lumen of the
newly forming ectosomes (Kalra et al., 2016). The mechanism of
this sorting has only recently started to unravel, and currently,
there are more questions than answers. Cytoplasmic proteins
are sorted to the lumen of budding ectosomes based on their
affinity to membrane lipids or proteins, as in sorting to ILVs
(van Niel et al., 2018). A portion of cytosolic proteins moves
to the lumen of ectosomes arbitrarily since their concentration
there resembles one in the cytosol (Meldolesi, 2018). Other
proteins, however, are actively sorted in the lumen of ectosomes,
which is suggested by their enrichment in these organelles.
The sorting may depend on the unspecific interactions with
the plasma membrane or specific sequence motifs. Fang
et al. (2007) demonstrated that plasma membrane-anchoring
and higher-order oligomerization target cytosolic proteins to
ectosomes (Fang et al., 2007; Shen et al., 2011). Alternatively,
proteins may enter the ectosome lumen via interaction with
transmembrane proteins or anchored complexes (Yang and
Gould, 2013).
All cell types can shed ectosomes under suitable stimulation;
the rate of shedding and type of stimuli inducing shedding,
however, varies considerably between cell types (Cocucci and
Meldolesi, 2015; Meldolesi, 2018). Induction of ectosome
shedding can result from activation of P2X7 receptor (by an
agonist or extracellular ATP), activation of PKC, an increase in
cytosolic free Ca2+, and from depolarization in neuronal cells
(Cocucci and Meldolesi, 2015; Toki et al., 2015; Meldolesi, 2018).
Most likely, ectosomal shedding is a limited process as it requires
significant membrane turnover.
Ectosomal secretion of tau is a poorly studied process with
only a few publications existing to date. This mechanism
of secretion, however, seems very plausible for tau.
First, tau has been detected in ectosomes purified from
multiple systems, including neuroblastoma cells, primary
cortical neurons, mouse ISF, and cerebrospinal fluid of
AD patients and healthy controls (Dujardin et al., 2014;
Spitzer et al., 2019). Second, tau possesses two capabilities
of proteins enriched in the lumen of ectosomes: tau can
(1) bind to the plasma membrane; and (2) form higher-
order oligomers (Fang et al., 2007; van Niel et al., 2018).
Interestingly, also FGF2 seems to be able to escape cells
in ectosomes, suggesting that the same mechanisms may
support both the membranous pore formation and sorting
to ectosomes (Taverna et al., 2003; Schiera et al., 2007;
Proia et al., 2008).
Thus, tau is likely secreted via two types of vesicles in both
health and disease—exosomes and ectosomes. Exosomes are the
main type of vesicles for tau secretion in both conditions but in
healthy cells as compared to the cells modeling tau pathology a
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larger proportion of tau is secreted via ectosomes (Dujardin et al.,
2014; Spitzer et al., 2019).
THE ROLE OF NEURONAL ACTIVITY IN
TAU SECRETION
Although cell-to-cell transmission of tau does not exclusively
rely on synaptic contacts, the formation of such contacts and
neuronal activity appears to promote secretion and spreading
of tau (Yamada et al., 2014; Calafate et al., 2015; Schultz et al.,
2018). While the role of neuronal activity in tau uptake has
not been examined, several studies have demonstrated its effect
on tau secretion (Pooler et al., 2013; Yamada et al., 2014;
Wang et al., 2017).
Neuronal contacts may simply serve as a favorable location
for tau secretion due to their unique composition of proteins and
lipids. For instance, synapses may concentrate specific HSPGs
with a high affinity for tau to facilitate its translocation through
the plasma membrane. One of the HSPGs concentrated at
synapses is syndecan-2, one of the major syndecans in neurons
(Hsueh et al., 1998; Hsueh and Sheng, 1999). Whether this
HSPG has a particular role in tau secretion is unknown, but a
recent study suggested that all members of the syndecan family
can promote tau internalization in cultured cells and therefore
may also have a role in its secretion (Hudák et al., 2019). The
MAPS co-chaperone DNAJC5 is another protein mediating tau
secretion that is abundantly present at presynaptic terminals,
where it regulates proteostasis of synaptic proteins together with
Hsc70 (Tobaben et al., 2001; Sharma et al., 2011).
Depolarization of the synaptic terminal may further support
various mechanisms of unconventional protein secretion. For
instance, neuronal activity can enhance tau secretion via
membranous organelles and ectosomes as these secretion
mechanisms would respond to Ca2+ influx induced by membrane
depolarization at the axon terminal (Rodríguez et al., 1997;
Burgoyne and Clague, 2003; Lachenal et al., 2011; Meldolesi,
2018). While the role of neuronal activity in ectosomal
tau secretion has not been examined, its positive effect
on the secretion of tau inside exosomes has been shown
(Wang et al., 2017).
Pooler et al. (2013) however, have demonstrated that neuronal
activity promotes largely non-exosomal secretion of tau in
primary neurons (Pooler et al., 2013). Furthermore, they showed
that tau secretion depended on Ca2+ influx following stimulation
of AMPA receptors, but only because Ca2+ promoted the
fusion of synaptic vesicles (SVs) with the plasma membrane
upon stimulation. Pooler et al. (2013) concluded that neuronal
activity promotes tau secretion via a mechanism dependent
on SV release—which does not necessarily mean that tau is
secreted via synaptic vesicles. Although hyperphosphorylated
and oligomeric tau indeed binds to the cytosolic side of SVs
via their transmembrane protein synaptogyrin-3, it is unlikely
that tau traverses the membrane of SVs and undergoes release
together with neurotransmitters (Zhou et al., 2017; McInnes
et al., 2018). Secretion via plasma membrane translocation
pathway, on the other hand, could explain the effect observed by
Pooler et al. (2013).
SVs release neurotransmitters by merging with the synaptic
membrane, from where the components of SVs are later retrieved
to replenish the pool of SVs by endocytosis (Chanaday et al.,
2019). As the protein and lipid compositions of the presynaptic
and the SV membranes differ, their fusion may transiently alter
the composition of the presynaptic membrane at least in the
timespan between fusion and retrieval (Takamori et al., 2006;
Lewis et al., 2017). This may make the PM more suitable for
tau exit by bringing proteins or lipids favoring tau secretion. As
tau associates with SVs, the fusion can also bring the normally
cytosolic Tau to the PM (Zhou et al., 2017).
It remains unclear if the components of newly merged SVs
largely stay together in clusters or disperse into the synaptic
membrane and later regather for retrieval (Willig et al., 2006;
Opazo and Rizzoli, 2010; Opazo et al., 2010; Gimber et al., 2015).
While post-fusion clustering of SV proteins has been a subject
of several studies, if SV lipids remain together on the synaptic
membrane remains unclear. Studies in Drosophila have shown
that recycling and endocytosis of SVs require the presence of
sterols that keeps SV components as discrete domains at the
synaptic membrane (Dason et al., 2010, 2014). Furthermore,
it appears that sterols present in SVs, not the presynaptic
membrane, plays a key role in the cycling of SVs (Dason et al.,
2010). Thus, it is possible that after SV fusion, tau, arriving at
the presynaptic membrane with SVs, becomes associated with
cholesterol microdomains enriched with SV components, some
of which may favor tau secretion.
THE ROLE OF GLIA IN TAU PROPAGATION
Recent studies suggest that glial cells are critical players in the
tau propagation process (Asai et al., 2015; Narasimhan et al.,
2019). Glial cells, consisting of: (1) microglia; (2) astrocytes;
(3) oligodendrocytes; and (4) NG2-glia, provide support and
protection and therefore are essential for maintaining neuronal
functions. Microglia are the resident innate immune cells of
the brain involved in the regulation of neuroinflammation,
synaptic pruning, and the clearance of microbes, dying cells,
and protein aggregates (Colonna and Butovsky, 2017). Astrocytes
are complex cells that play diverse supportive functions in the
brain including maintenance of electrolyte and lipid homeostasis,
uptake and recycling of neurotransmitters, and modulation
of synaptic activity (Oksanen et al., 2019). Oligodendrocytes
produce the myelin sheath to insulate and metabolically
support axons, while NG2-glial cells serve as progenitors for
oligodendrocytes in the adult brain to support myelin plasticity
(Simons and Nave, 2015; Valny et al., 2017).
Although all types of glial cells are relevant to AD
pathogenesis, microglia and astrocytes have received the most
attention for their role in mediating neuroinflammation that
seems to play an important role in the pathogenesis of AD
(Heneka et al., 2015; Kinney et al., 2018). In response to injury
or pathological signals, such as Aβ and possibly pathological tau,
these glial cells adopt activated phenotype and start releasing
inflammatory factors such as cytokines and chemokines (Heneka
et al., 2015; Laurent et al., 2018). Although a lot of controversies
exist in this research area, it seems that at the early stages of AD, a
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neuroinflammatory response may be protective, resulting in the
efficient elimination of Aβ and pathological tau (Kinney et al.,
2018). The continuous activation of glial cells in the course of the
disease, however, may lead to the development of dysfunctional
chronic inflammation that exacerbates both AD pathologies.
Microglia can eliminate extracellular tau by phagocytizing
and degrading it (Asai et al., 2015; Luo et al., 2015; Bolós et al.,
2016; Hopp et al., 2018). Indeed, exposure of tau-containing
cell lysate to microglia reduced the seeding activity of this
lysate, confirming the ability of healthy microglia to degrade
seed-competent tau (Hopp et al., 2018). Degradation efficiency,
however, may worsen as microglia becomes dystrophic due to
the overloading of the clearance system (Vogels et al., 2019). As
a result, microglia may enhance tau propagation by secreting
tau-containing exosomes, which can propagate the pathology
more efficiently than naked pre-aggregated tau (Asai et al.,
2015; Hopp et al., 2018). In support of this, the inhibition
of exosome biosynthesis or microglia depletion was shown to
suppress tau propagation in mouse models of tauopathy and to
improve learning and memory in the 3xTg-AD mouse model
(APP Swedish, MAPT P301L, and PSEN1 M146V; Asai et al.,
2015; Dagher et al., 2015).
If tau phagocytosis by microglia eventually enhances tau
propagation, the important question here is where do microglia
take tau from? First, microglia may obtain tau by phagocytosis
of neurons or synapses containing pathological tau (Brelstaff
et al., 2018; Dejanovic et al., 2018). Alternatively, microglia may
phagocytize tau secreted to the extracellular space.
As microglia uptakes extracellular vesicles, exosomes can
deliver tau to microglia (Paolicelli et al., 2019). The majority
of neuronal exosomes secreted upon neuronal stimulation,
however, appear to bind specifically to neurons, not to glial cells,
suggesting that microglia likely receives the majority of tau not
via the uptake of tau-containing extracellular vesicles (Chivet
et al., 2014). Several studies demonstrated, on the other hand,
that microglia can phagocytize free tau, in both soluble and
insoluble forms (Asai et al., 2015; Luo et al., 2015; Bolós et al.,
2016). Thus, as free tau is present at a relatively high level in
the extracellular space and can be internalized to cells, it appears
to be a good candidate for the main source of tau ‘‘supply’’
for microglia.
Although less studied, astrocytes may also be a part of
the tau propagation process. As astrocytes are well integrated
into synapses both physically and functionally, they are
well-positioned to interfere with the synaptic transmission of
tau. Recent studies suggest that this may indeed be possible
(Narasimhan et al., 2017, 2019; Martini-Stoica et al., 2018;
Perea et al., 2019). First, astrocytes were shown to uptake tau
and suppress its spreading in vitro, suggesting a protective
role of these cells (Martini-Stoica et al., 2018; Perea et al.,
2019). In fact, in cell culture and organotypic brain slices,
astrocytes internalized oligomeric tau more efficiently than
neurons (Piacentini et al., 2017). It is noteworthy that while
uptake of naked monomeric and aggregated tau by cultured
astrocytes was observed in several studies, vesicular tau uptake
by astrocytes has not been examined (Piacentini et al., 2017;
Martini-Stoica et al., 2018; Perea et al., 2019).
Development of astrocytic tau inclusions in multiple
tauopathies may also suggest that astrocytes uptake neuronal
tau as its expression in these cells is very low (Kahlson and
Colodner, 2015). In support, when propagation of neuronal
and glial tau pathology was investigated in wild-type mice
following the injection of tau extracted from CBD or PSP patient
brains to gray matter, astrocytic tau pathology spread into
the same brain regions as neuronal pathology (Narasimhan
et al., 2017). Furthermore, the intensity of tau pathology in
astrocytes negatively correlated with that of neurons, again
suggesting uptake of neuronal tau by astrocytes. Finally, when
mice with neuron-specific tau knockdown were used for the
same experiment, astrocytic tau pathology failed to spread,
suggesting that the spread of tau pathology in astrocytes requires
uptake of neuronal tau (Narasimhan et al., 2019). It is possible,
however, that certain stressors during disease progression
could upregulate the expression of tau in astrocytes to the level
sufficient to initiate tau pathology.
Irrespective of the origin of tau in astrocytes, an important
question is whether astrocytes can pass tau to neurons.
Indeed, astrocytes appear to be capable of tau secretion as a
recent study demonstrated that in comparison with neuronal
exosomes, astrocytic exosomes in human plasma contained
several-fold higher levels of hyperphosphorylated tau (Goetzl
et al., 2016). Additionally, in certain brain areas of tauopathy
patients, the appearance of tau pathology in astrocytes precedes
its appearance in neurons (Ling et al., 2016; Kovacs et al.,
2020). Furthermore, in ARTAG, tau pathology can be present
exclusively in astrocytes (Kovacs et al., 2016). Finally, following
injection to wild-type mice brain, tau extracted from brains of
ARTAG patients without neuronal tau pathology resulted in a
spread of hyperphosphorylated tau in both neurons and glia,
suggesting that astrocytic tau seeds are capable of initiating
the disease progression (Ferrer et al., 2018). The absence of
observable tau pathology in neurons, however, does not mean
the absence of pathological neuronal tau able to seed aggregation
(DeVos et al., 2018).
In addition to astrocytes, tau-positive inclusions can also
appear in oligodendrocytes in tauopathies, and oligodendrocytes
do express tau, although at a low level (Kahlson and Colodner,
2015). As with astrocytes, oligodendrocytic tau pathology
can spread in the brain of wild-type mice, following the
injection of brain extracts from CBD and PSP patients to the
gray matter (Narasimhan et al., 2017). In contrast, however,
oligodendrocytes were able to propagate CBD oligodendrocytic
tau pathology across the brain even in mice with neuron-
specific tau knockdown (Narasimhan et al., 2019). Furthermore,
oligodendrocytes seemed not to use neurons for the propagation
process at all, suggesting a completely independent mechanism
of tau propagation in these cells with seeds transferring from
one oligodendrocyte to another. Interestingly, injection of tau
from AD patients into gray matter failed to result in the
spreading of tau pathology in oligodendrocytes (Narasimhan
et al., 2017). In contrast, tau injection into the white matter
of wild-type mice resulted in tau propagation, even when
injected tau was extracted from tauopathies with only neuronal
inclusions, AD and PART (Ferrer et al., 2019). Thus, it
Frontiers in Molecular Neuroscience | www.frontiersin.org 12 September 2020 | Volume 13 | Article 569818
Merezhko et al. The Cell Biology of Tau Secretion
appears that although oligodendrocytes can spread tau pathology
independently, uptake of neuronally secreted tau may trigger the
development of such pathology.
CONCLUSIONS
Neurons appear to propagate tau pathology in a variety of
ways, which are at least partially modulated by neuronal activity
and involve multiple cell types in the brain. Unconventional
pathways of tau secretion are likely deeply intertwined with
each other, and manipulating one secretory pathway is
likely to affect others, complicating mechanistic studies.
Naturally, like many processes in neurons, tau secretion
does not function independently of neuronal activity. The
mechanism of such connection, however, is currently not clear
and remains on the most intriguing unanswered questions
regarding the tau secretion. Our current understanding
of relationships between glial cells and different steps
of tau propagation is also limited and would require
further in vivo research as well as a more complex in vitro
approaches that could integrate multiple cell types and other
contributing factors.
Tau secretion occurs via multiple pathways, but it is not clear
if the pathways under pathological and physiological conditions
are the same or only partially overlapping. Furthermore, from
the propagation perspective, not all secreted tau is the same.
Tau secreted through different pathways may have different
uptake and seeding abilities. Finally, the mechanistic similarities
and differences involved in cell-to-cell transmission of different
pathologically misfolded proteins require further attention. In
summary, the field of pathological propagation of misfolded
proteins in neurodegenerative diseases has only recently emerged
and will undoubtedly offer many years of exciting research which
hopefully, in the end, can be translated to the benefit of numerous
patients in need of better treatments.
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